$ATEC

Alphatec lowers FY 2026 revenue outlook to $862M while targeting 16% adjusted EBITDA margin (NASDAQ:ATEC)

Alphatec (ATEC) reported Q3 2026 revenue of $221M, up 13% YoY, but below expectations. The company lowered its FY 2026 revenue outlook to $862M and targets a 16% adjusted EBITDA margin. Management cited strong demand for surgical solutions.

Original reporting
Published Oct 30, 2026, 2:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 2:06 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ATEC
Bearish
high confidence
Mentioned
$ATEC
Relevance
8/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$ATECBearishHigh
01

Why it matters

The reduced FY 2026 revenue outlook could trigger a sell‑off, while the Q3 growth may temper the decline.

02

Market read

Guidance cut is a primary corporate event that can move the stock and affect the medical‑device sector.

03

What to watch

Strong demand for surgical solutions and 13% Q3 revenue growth may indicate resilience despite lower FY outlook.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Alphatec Holdings provides surgical devices and reported Q3 results with revenue growth, but lowered its full‑year revenue guidance.

Company-level read

Ticker impact

$ATECBearishHigh confidence
Context

Alphatec lowered its FY 2026 revenue outlook to $862M and reported Q3 revenue of $221M, up 13% YoY.

Expected impact

downward pressure as the market prices in the reduced revenue outlook

Evidence & confidence

Revenue guidance drop suggests lower earnings potential, prompting investors to reassess valuation.

Market effects

Medical‑device sector may face slight headwinds as a peer's guidance is cut.

U.S. small‑cap market could see modest downside pressure.

Limited to U.S. equities; no broader macro impact.

Counterpoint

The guidance cut may be temporary; upcoming product launches could offset revenue shortfall.

Key entities

  • Alphatec Holdings

    Medical‑device manufacturer

  • Patrick Miles

    Chairman, CEO & President of Alphatec

Related articles

$ATECMedAI 8/10

Alphatec Q3 Earnings Call Highlights

Alphatec reported Q3 earnings with higher margins (72%) and positive free cash flow ($6M). Full-year 2026 revenue guidance was reduced to $862M due to market softness and supply constraints. The company highlighted growth in EOS and Valence platforms. Alphatec ended the quarter with $135M in liquidity.

$ATECMedAI 8/10

ATEC Reports Third Quarter Financial Results – Ortho Spine News

Alphatec Holdings (ATEC) reported Q3 2026 revenue of $221M, up 13% YoY, with surgical revenue at $202M, up 14%. Adjusted EBITDA was $38M, or 17% of revenue, up 400 bps YoY. Case volumes grew 20% and new surgeon users increased 25%. The company expects full-year 2026 revenue of $862M, adjusted EBITDA of $137M, and $10M in free cash flow.

$ATECMedAI 8/10

Alphatec: Q3 Earnings Snapshot

Alphatec Holdings Inc. (ATEC) reported a Q3 loss of $5.5 million, or 3 cents per share, with adjusted earnings of 9 cents per share. Revenue was $221.2 million, missing estimates of $224.3 million. The company expects full-year revenue of $862 million. ATEC shares have fallen 46% YTD and 31% over the past year.

$ATECMed

ATEC Reports Third Quarter Financial Results

Alphatec Holdings, Inc. (ATEC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ATEC Reports Third Quarter Financial Results Total revenue of $221 million, up 13% year-over-year Surgical revenue of $202 million increased 14% Case volumes grew 20% and net new surgeon users increased 25% CARLSBAD, Calif., October 29, 2026 – Alphatec Holdings, Inc.